While control cells were able to form tumors at 6 out of 8 injection site, the tumor forming ability of SREBP1 and SREBP2 knockdown cells was decreased (Fig. 7h), suggesting that silencing SREBPs inhibits tumor initiation. Here, SREBF1 is linked to neoplasm.